Abstract Cellular mechanisms have been proposed in the pathogenesis of fibrotic processes in the kidney. In this setting, cell sources underlying the generation of matrixproducing cells in diseased kidneys have been categorized as activated resident stromal cells (e.g., fibroblasts, pericytes), infiltrating bone-marrow-derived cells (e.g., fibrocytes, T cells, macrophages), and cells derived from epithelial-mesenchymal transition/endothelial-mesenchymal transition. Among these cell sources, accumulating evidence has shed light on the involvement of bone-marrow-derived cells, including monocytes/macrophages, and a circulating mesenchymal progenitor cell, fibrocyte, in the progression of fibrosis in kidney. Bone-marrow-derived cells positive for CD45 or CD34, and type 1 (pro)collagen dependent on the chemokine and renin-angiotensin systems migrate into diseased kidneys and enhance synthesis matrix protein, cytokines/chemokines, and profibrotic growth factors, which may promote and escalate chronic inflammatory processes and possible interaction with resident stromal cells, thereby perpetuating kidney fibrosis.
Introduction
Fibrosis is a characteristic hallmark that determines the prognosis of any kind of progressive kidney disease and leads to kidney failure. The histological characteristics of interstitial fibrosis in the kidney are evidenced by the presence of tubular atrophy and dilation, interstitial leukocyte infiltration, accumulation of fibroblasts, and increased interstitial matrix deposition [1] . In this aspect, there is accumulating evidence that cellular mechanisms driving fibrosis are involved [2] . Cell sources underlying the generation of matrix-producing cells in diseased kidneys have been categorized as follows: (1) activated resident stromal cells (e.g., fibroblasts, pericytes), (2) infiltrating bone-marrow-derived cells (e.g., fibrocytes, T cells, macrophages), (3) epithelial-mesenchymal transition (EMT)/endothelialmesenchymal transition (EndMT) [3] [4] [5] (Fig. 1) .
Among cells responsible for kidney fibrosis, fibrocytes, originally identified in 1994 as a circulating bone-marrowderived CD34
? cell population of fibroblast-like cells, were reported to infiltrate from inflammatory exudates into a subcutaneously implanted wound chambers [6] . Accumulating evidence suggests that fibrocytes, uniquely comprising a minor fraction of the circulating pool of leukocytes (\1%), are candidates for participating in organ fibrosis associated with conditions in lungs, skin, visceral fibrosis, heart, liver, and kidneys, as well as in physiological roles such as wound repair, cochlear physiology, and auditory function [7, 8] . In addition, a recent study revealed that the delicate balance of peroxisome-proliferator-activated receptor gamma and transforming growth factor (TGF)-beta 1 activation drives the selection of an adipocyte or myofibroblast differentiation pathway through stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) signaling [9] . Originally, fibrocytes were identified by CD34 and collagen-1 coexpression [6, 7] . A recent study revealed that markers (CD45RO, 25F9, S100A8/A9) distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts [10] . However, identification of markers specific to fibrocytes remains to be investigated. Fibrocytes may be identified by dual positivity of CD34 or CD45 and collagen-1 or procollagen-1 [6, 7] . In this manuscript, we focus on the involvement of bone-marrowderived cells in the pathogenesis of kidney fibrosis.
Detection of cells dual positive for CD34 or CD45 and type 1 collagen in kidney fibrosis
The detection and role of fibrocytes in progressive kidney fibrosis remains to be investigated. Using immunostaining and flow cytometry analyses, we uncovered CD45 and type 1 collagen dual-positive (CD45 ? /Col1 ? ) cells infiltrating the interstitium, especially the corticomedullary regions, in progressive kidney fibrosis induced by ureteral ligation in mice [11] (Fig. 2a) . The number of infiltrating fibrocytes increased with fibrotic progression after ureteral ligation, reaching a peak on day 7 (Fig. 2b) . To further verify the existence of fibrocytes, dual immunostainings of CD34 and type 1 collagen were also performed. The infiltration of CD45
? /Col1 ? cells was also observed in the interstitium and correlated with disease progression.
These findings prompted us to explore the presence of CD45
? /proCol1 ? cells infiltrating into human kidneys, including in people with diabetic nephropathy. The number of infiltrating CD45
? /proCol1 ? cells in the interstitium correlated well with the severity of tubulointerstitial lesions, such as interstitial fibrosis, the number of CD68-positive macrophages, and urinary monocyte chemoattractant protein-1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) levels in patients with chronic kidney disease. In particular, there was an inverse correlation between the number of interstitial CD45
? /proCol1 ? cells and kidney function at the time of biopsy [12] . The number of interstitial CD45
? /proCol1 ? cells and macrophages, as well as urinary MCP-1/CCL2 levels were significantly decreased during convalescence induced by glucocorticoid therapy. Collectively, these results suggest that CD45
? /proCol1
? cells may be involved in the pathogenesis of chronic kidney disease, leading to kidney fibrosis through the interaction with macrophages and MCP-1/CCL2.
Chemokine system involved in infiltration of bone-marrow-derived cells dual positive for CD34 or CD45 and type 1 collagen into kidney
It is of note that fibrocytes isolated from humans and mice express chemokine receptors, such as chemokine (C-C motif) receptor (CCR)2, CCR3, CCR5, CCR7, and CXCR4, thereby regulating the recruitment to sites of fibrosis [7, 11, [13] [14] [15] . Supporting this notion, intradermal instillation of secondary lymphoid tissue chemokine (SLC)/CCL21 was first described to induce recruitment of fibrocytes at the injected site [16] . In addition to skin lesions, CCR7-expressing infiltrating cells, also positive for type 1 collagen (CCR7 ? /Col1 ? ), were detected in diseased kidneys 7 days after ureteral ligation in wild-type mice [11] . 37 ? cells in obstructed kidneys was increased to 7.9% of the total isolated renal cells compared with that in normal (0.25%) and contralateral (0.21%) kidneys. Of these CCR7-expressing cells in obstructed kidneys, 66.5% were CXCR4 ? /CCR2 ? , 16.8% were CXCR4 ? /CCR2 -, 4.3% were CXCR4
-/CCR2 ? , and 12.4% were CXCR4 -/CCR2 cells. The impact of CCL21/CCR7 signaling on progressive kidney interstitial fibrosis was further examined. Mean interstitial fibrosis and the amount of hydroxyproline were reduced by almost 50% in mice treated with anti-CCL21 antibodies compared with that in wild-type mice 7 days after ureteral ligation, which was confirmed by the similar reduction in CCR7-null mice [11] . Accordingly, based on the finding that treatment with anti-CCL21 antibodies or CCR7 deficiency resulted in[50% reduction in the number of CD45
? /Col1 ? cells, CCL21/CCR7 signaling is thought to be the major pathway attracting CD45
? /Col1 ? cells into the kidney in this particular model [11] . Interestingly, blockade of CCL21/CCR7 signaling reduced the number CCR2-expressing infiltrates in immunohistochemical studies, along with renal transcripts of MCP-1/CCL2. In vitro studies also revealed that stimulation of cultured CD45 ? / Col1
? cells with angiotensin II enhanced the expression of messenger RNA (mRNA) of type 1 collagen and TGF-beta [17] . These findings further suggest that CD45
? /Col1 ? cells may contribute to kidney fibrosis by producing MCP-1/ CCL2 and TGF-beta, which may be responsible for chronic persistent inflammatory processes and activation of resident stromal cells (e.g., fibroblasts, pericytes) and the process to EMT/EndMT, in addition to collagen synthesis of CD45
? / Col1
? cells. All these events may orchestrates downstream antibodies and in chemokine (C-C motif) receptor 7 (CCR7)-null mice compared with that in wild-type mice 7 days after ureteral ligation. Values are mean ± standard error of mean. c By flow cytometry analyses, fibrocytes increased in number in bone marrow cells, which were enhanced in angiotensin type 2 receptor (AT2R-null mice with ureteral ligation fibrotic events, eventually resulting in kidney fibrosis (Fig. 1) .
Renin-angiotensin system and bone-marrow-derived cells dual positive for CD45 and type 1 collagen
The renin-angiotensin system (RAS) is one of the major pathways in the pathogenesis of fibrotic conditions and is possibly dependent on two major distinct receptors, designated as angiotensin II receptor type 1 (AT1R) and angiotensin II receptor type 2 (AT2R). We hypothesized that CD45
? /Col1 ? cells might contribute to kidney fibrosis dependent on the RAS. In a murine model, the extent of kidney fibrosis in AT2R-deficient mice was more evident, concomitant with the larger number of infiltrating CD45
? cells in fibrotic kidneys [17] . Interestingly, CD45 ? / Col1
? cell numbers in bone marrow were also increased in mice with ureteral ligation, especially in AT2R-deficient mice (Fig. 2c) . In the therapeutic points of view, pharmacologic inhibition of AT1R reduced the degree of kidney fibrosis as well as the number of CD45
? /Col1 ? cells in both the kidney and bone marrow. AT1R inhibition also decreased the angiotensin-II-stimulated expression of type 1 collagen synthesis in isolated human CD45
? /Col1 ? cells, whereas an AT2R inhibitor augmented the expression of mRNA of type 1 collagen. These results suggest that AT1R/AT2R signaling may contribute to the pathogenesis of kidney fibrosis by at least two mechanisms: (1) by regulating the number of CD45
? /Col1 ? cells in bone marrow, and (2) by activation of these cells [17] .
Fibrocytes: possible clinical biomarker for fibrotic disease
Clinical biomarkers for reflecting fibrogenic activity and indicating disease progression are required in various fields. Moeller et al. reported that fibrocytes defined as cells positive for CD45 and collagen 1 were significantly elevated in patients with stable idiopathic pulmonary fibrosis (IPF), with a further increase during acute disease exacerbation. Fibrocyte numbers were an independent predictor of early mortality. The mean survival of patients with fibrocytes [5% of total blood leukocytes was 7.5 months compared with 27 months for patients with\5%. Thus, the authors concluded that circulating fibrocytes in patients with IPF are an indicator for disease activity of IPF and might be useful as a clinical marker for disease progression [18] . Supporting this notion, the number of interstitial CD45
? /proCol1 ? cells was significantly decreased during convalescence induced by glucocorticoid therapy in patients with chronic kidney diseases [12] . Further studies are required to provide evidence that counting fibrocyte numbers might be a biomarker for activity and progression of fibrotic conditions.
Involvement of monocytes/macrophages in kidney fibrosis
Recent studies reveal that macrophage diversity in response to their microenvironment, which uncovers their roles in kidney injury, raising therapeutic possibilities to attenuate kidney fibrosis [19, 20] . In our viewpoint, human peripheral CD14-positive monocytes/macrophages directly contribute to producing type 1 collagen, resulting in fibrogenesis, and are dependent on an amplification loop of MCP-1/CCL2-CCR2 [21] . In addition, the presence of MCP-1/CCL2 expression is suggestive of a chronic stage of disease, especially in tubulointerstitial lesions and urinary levels of protein excretion, despite renal etiologies through the recruitment and activation of macrophages. As is well known, urinary protein excretion promotes and escalates tubulointerstitial lesions, resulting in kidney fibrosis. Moreover, the measurement of urinary MCP-1/ CCL2 levels is a useful clinical tool for monitoring the disease activity of inflammatory renal disorders, including diabetic nephropathy [22] [23] [24] [25] . This was supported by the fact that blockade of MCP-1/CCL2 prevented leukocyte migration to the kidney, urinary protein excretion, and TGF-beta expression, thereby preventing glomerulosclerosis and interstitial fibrosis [23, [26] [27] [28] . In addition to MCP-1/CCL2-CCR2, blockade of fractalkine-CX3CR1 also reduced kidney fibrosis, which was concomitant with reduction in macrophage infiltration [29] . CCR2 receptor is expressed in glomerular podocytes, suggesting MCP-1/ CCL2 activation of CCR2 on podocytes may underlie induction of MMP-12, leading to glomerular basement membrane damage and urinary protein excretion [30] . Finally, it is of note that there were significant correlations between the numbers of CD45
? /proCol1 ? cells and macrophages in human kidneys as well as urinary levels of MCP-1/CCL2, suggesting the close relationship of CD45
? / proCol1
? cells with macrophages. Based on these results, we propose the MCP-1/CCL2-CCR2 axis on recruitment and activation of bone-marrow-derived cells, especially macrophages, plays a role in the pathogenesis of tubulointerstitial lesions, resulting in kidney fibrosis despite kidney etiologies (Fig. 3) .
Involvement of T cells in kidney fibrosis
The degree of fibrosis is related to leukocyte infiltration. Tapmeier et al. [31] examined the role of different T-cell populations on kidney fibrosis in the mouse model of unilateral ureteral obstruction. They found a critical role for CD4
? T cells in kidney fibrosis. In addition, NikolicPaterson [32] describes modulation of T cells in the process of kidney fibrosis: (1) T cells may act directly on fibroblasts and pericytes to promote their migration, proliferation, and differentiation, resulting in accumulation of alpha smooth-muscle actin (SMA ? ) myofibroblasts, which synthesize and deposit interstitial matrix; (2) T cells may induce a profibrotic phenotype in the infiltrating macrophage population, which, in turn, secretes profibrotic and pro-proliferative cytokines and growth factors that induce fibroblast migration, proliferation, and differentiation; (3) T cells may act directly on tubular epithelial cells to induce secretion of cytokines and growth factors that, in turn, act on fibroblasts.
Stromal cell activation and myofibroblast generation in kidney fibrosis
Activation of local stromal cells (e.g., fibroblasts and pericytes) and generation of myofibroblasts from epithelial cells (via EMT), pericytes, endothelial cells (via EndMT), and bone-marrow-derived cells are key processes in tubulointerstitial fibrosis [33] . For 15 years, EMT has been viewed as a principle source of fibroblasts in tissue fibrosis [34] . In addition to tubular epithelial cells, glomerular podocytes [35] and endothelial cells [36, 37] undergo transition after injury and have been reported to be involved in kidney damage, resulting in fibrosis. More recently, in the process of perpetuation of fibrogenesis, hypermethylation of RASAL1, encoding an inhibitor of the Ras oncoprotein, is associated with the perpetuation of fibroblast activation and fibrogenesis in the kidney [38] . In contrast, Duffiels et al. report that pericytes and perivascular fibroblasts are primary sources of collagen-producing cells in kidney fibrosis [39, 40] . Therefore, further studies are required to determine the degree to which processes including those resulting from bone-marrow-derived cells contribute to kidney fibrosis.
Concluding remarks and future directions
A deep insight into bone-marrow-derived cells dependent on the chemokine and RAS systems provides a key for the novel pathogenesis of progressive organ fibrosis, including kidney fibrosis. In addition to those systems, our recent unpublished data suggest the possible involvement of CD45
? /Col1 ? cells in diabetic nephropathy, which is supported by the evidence that CD45
? /proCol1 ? cells are detected in human diabetic nephropathy [12] . Further studies for biology of bone-marrow-derived cells and the interaction of resident stromal cells would be required for a better understanding and the therapeutic benefit for kidney fibrosis. 
